A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non-small cell lung cancer

Trial summary:

To assess the safety and determine the recommended phase II dose (RP2D) of DNA damage response inhibitors (DDRi) to be used in combination with radical thoracic radiotherapy in stage IIB/III non-small cell lung cancer (NSCLC). Five different inhibitors will be applied, each on a different study arm aiming to get approximately 30 patients in each experimental arm treated with DDRi + Radiotherapy and approximately 50-60 patients treated with RT alone. Total accrual is estimated to 210 patients in 6 years.

RT QA summary:

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.

QA ProcessQA ActivityRequired for TrialAdditional Details
Pre-AccrualFacility Questionnaire
Outlining Benchmark Case
Planning Benchmark Case
Dummy Run
During AccrualIndividual Case Review
Data collectionAll patients
QA StreamliningADSCAN, Isotoxic IMRT

RTTQA contact: concordeqa.enh-tr@nhs.net

Chief investigator: Dr Alastair Greystoke / Dr Corinne Faivre-Finn

Sponsor: University of Leeds  ctru_concorde@leeds.ac.uk

Funder: CRUK, AstraZeneca